An interventional study of Radiofrequency Ablation (RFA) for Perianal Fistula in Rectal Fistulas, sponsored by Korea University Ansan Hospital. Not yet recruiting. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by Korea University Ansan Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this pilot clinical study is to learn whether radiofrequency ablation (RFA) can safely and effectively treat perianal fistulas in adults. It will also evaluate procedure-related safety and changes in symptoms over time. The main questions it aims to answer are:
Participants will:
Perianal fistula is a chronic inflammatory tract that can cause persistent discharge, pain, recurrent abscess formation, and substantial impairment in daily activities and quality of life. While definitive surgical management aims to eradicate the fistula while preserving sphincter function, conventional approaches may be limited by variable healing rates, risk of recurrence, and concerns regarding sphincter injury and subsequent continence disturbance-particularly in complex fistulas or in patients at higher risk of incontinence. As a result, sphincter-preserving, minimally invasive techniques have been actively explored to improve clinical outcomes while minimizing functional compromise.
Radiofrequency ablation (RFA) is a thermal energy-based modality that can induce controlled tissue coagulation and remodeling. For perianal fistula treatment, RFA has the potential to ablate the fistula tract internally and promote tract closure without dividing sphincter muscles. However, a key challenge in energy-based fistula treatments is achieving consistent and uniform ablation along the entire tract length, because uneven energy delivery may lead to insufficient ablation in certain segments and treatment failure or recurrence. To address this limitation, a novel, dedicated RFA fistula device has been developed to deliver thermal energy in a standardized manner along the tract, with the intent of achieving more uniform ablation across tract segments (ie, segment-by-segment energy delivery rather than focal "dot" ablation). Prior preclinical work using a porcine perianal fistula model was performed to establish feasible operating parameters and to support translation to a first-in-human clinical pilot study.
Objectives The primary objective of this prospective multicenter single-arm pilot study is to evaluate the clinical efficacy of a novel RFA device for the treatment of perianal fistula in adult participants, with clinical fistula closure assessed at 6 months after the procedure. Secondary objectives are to evaluate safety (procedure- and device-related adverse events), recurrence patterns during follow-up, and changes in symptom burden and functional outcomes over time. In addition, this pilot study aims to assess procedural feasibility and to generate data that will inform the design of larger confirmatory studies, including refinement of outcome definitions, follow-up strategy, and operational standardization across sites.
Methods This is a prospective, multicenter, single-arm pilot interventional study enrolling adult participants with perianal fistula who are considered appropriate for a sphincter-preserving approach. All enrolled participants will receive RFA treatment using the dedicated fistula RFA device under a standardized procedural framework across participating sites.
Intervention (RFA procedure):
RFA will be delivered intraluminally to the fistula tract using the dedicated RFA catheter introduced via the external opening according to the standardized technique. The procedure is designed to apply controlled thermal energy along the tract to promote tract closure while minimizing injury to surrounding sphincter structures. Periprocedural management and post-procedure care will follow a harmonized protocol across sites to support consistent implementation and safety monitoring.
Follow-up and assessments:
Participants will be evaluated longitudinally after the procedure, with key clinical assessments at approximately 3 and 6 months post-procedure (in addition to immediate post-procedure assessment per routine clinical care). Clinical evaluation will include inspection and digital rectal examination to assess fistula healing status and to identify any signs of persistent or recurrent disease. Safety monitoring will include collection and documentation of adverse events from the time of the procedure through the final follow-up assessment, including severity and relationship to the procedure/device. Patient-reported symptoms (including pain) and functional outcomes (including continence-related measures and quality-of-life measures when applicable) will be captured at predefined time points.
Endpoints overview:
The primary endpoint is clinical fistula closure at 6 months after RFA treatment, based on standardized clinical criteria. Secondary endpoints include recurrence during follow-up, safety outcomes (adverse events/serious adverse events), symptom trajectories (eg, pain), functional outcomes (eg, continence), quality of life measures, and the need for additional fistula-related interventions.
Data analysis:
As a pilot study, analyses will primarily be descriptive and estimation-focused to characterize preliminary efficacy and safety signals. Outcome measures will be summarized using appropriate descriptive statistics, and clinically relevant proportions (eg, closure and recurrence rates) will be reported with confidence intervals where applicable. The resulting data will be used to inform sample size assumptions, endpoint operationalization, and protocol optimization for subsequent larger-scale studies.
170 studies on the registry are indexed under Rectal Fistula; 45 are open to participants now.
This study's planned enrollment of 80 is above the median of 66 across 116 interventional studies indexed under Rectal Fistula.
Browse Rectal Fistula studies →Korea University Ansan Hospital is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with one or more of the following perianal fistula types:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this single-arm, prospective multicenter pilot study will undergo radiofrequency ablation (RFA) for treatment of perianal fistula using a standardized procedural protocol across sites. Clinical outcomes and safety will be assessed longitudinally through follow-up, with the primary clinical assessment at 6 months after the procedure.
Device: Radiofrequency Ablation (RFA) for Perianal Fistula
Radiofrequency ablation (RFA) will be delivered to the fistula tract using a dedicated RFA catheter introduced through the external opening under standardized technique. The procedure aims to apply controlled thermal energy along the tract to promote tract closure while minimizing injury to surrounding sphincter structures. Participants will receive a single RFA treatment per protocol, with post-procedure care and safety monitoring during scheduled follow-up.
Fistula Closure (Clinical Healing)
Fistula closure will be determined by clinical assessment, defined as: (1) complete epithelialization/absence of the external opening on inspection, (2) no drainage/discharge (spontaneous or on gentle pressure), and (3) no clinically apparent fistula tract opening on digital rectal examination (DRE). Symptom improvement (including reduced pain) will be recorded as supportive patient-reported information.
Time frame: Baseline(post-procedure) and at 3 and 6 months after RFA
Fistula Recurrence
Recurrence after initial clinical closure, defined as reappearance of an external opening, recurrent drainage/discharge, or clinical evidence of a fistula tract on examination during follow-up.
Time frame: Up to 6 months after RFA (assessed at 3 and 6 months)
Time to Fistula Closure
Time from the RFA procedure to first documented clinical closure as defined in the primary outcome criteria.
Time frame: Up to 6 months after RFA
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number and proportion of participants experiencing procedure- or device-related AEs/SAEs (eg, bleeding, infection/abscess, urinary retention, severe pain requiring intervention, hospitalization, or reoperation), graded by severity and relationship to the procedure/device.
Time frame: From the day of procedure through 6 months after RFA
Change in Pain Severity
Change in patient-reported pain interference compared with baseline, assessed using the PROMIS® Pain Interference - Short Form 8a. The instrument includes 8 items, each scored on a 5-point Likert scale (1=not at all to 5=very much). Item scores are summed to generate a raw total score ranging from 8 to 40, with higher scores indicating worse pain interference. The outcome will be reported as the change in raw total score from baseline at each follow-up time point.
Time frame: Baseline (pre-procedure), 3 months, and 6 months after RFA
Change in Fecal Continence
Change in continence status assessed by a validated score (Wexner/St. Mark's incontinence score), compared with baseline.
Time frame: Baseline, 3 months, and 6 months after RFA
Change in Health-Related Quality of Life
Change in quality of life using a validated patient-reported measure (PROMIS), compared with baseline.
Time frame: Baseline, 3 months, and 6 months after RFA
Need for Additional Fistula-Related Intervention
Proportion of participants requiring additional fistula-related procedures or treatments during follow-up (eg, drainage, seton placement, repeat ablation, or surgery).
Time frame: Up to 6 months after RFA
Patient Global Impression of Improvement (PGI-I)
Patient-reported global improvement using a single-item global rating (PGI-I)
Time frame: 3 months and 6 months after RFA
Procedural Feasibility and Technical Success
Successful completion of the planned RFA procedure per protocol (eg, ability to access the tract and deliver energy as intended) without intra-procedural device failure.
Time frame: During the procedure (day of RFA)
Procedure Duration
Procedure duration, defined as the time recorded in the operative report from the start of the fistula procedure to completion (minutes).
Time frame: Day of procedure
Same-day Discharge
Proportion of participants discharged on the day of the procedure (post-procedure day 0), recorded as Yes/No.
Time frame: Day of procedure (post-procedure day 0)
Time to Return to Normal Activity
Time (days) from the procedure to return to usual/normal daily activities, as reported by the participant.
Time frame: Up to 30 days after RFA procedure
No study locations are listed for this record.
Plan to share: Undecided
Start is estimated for Apr 2026; primary completion for Jan 2027, 9 months later.
Of 54 non-industry interventional studies with no phase under Rectal Fistula, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 36. This study's planned 9 months is below that.
Counting every sponsor, half of 58 studies reached it within 27 months; a quarter within 11 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Korea University Ansan Hospital